title: Joint commission primary stroke centers utilize more rt-PA in the nationwide inpatient sample.
abstract: BACKGROUND
  The Joint Commission began certifying primary stroke centers (PSCs) in December 2003 and provides a standardized definition of stroke center care. It is unknown if PSCs outperform noncertified hospitals. We hypothesized that PSCs would use more recombinant tissue plasminogen activator (rt-PA) for ischemic stroke than would non-PSCs.
  
  
  RESULTS
  Data were obtained from the Nationwide Inpatient Sample from 2004 to 2009. The analysis was limited to states that publicly reported hospital identity. All patients ≥18 years with a primary diagnosis of acute ischemic stroke were included. Subjects were excluded if the treating hospital was not identified, if it was not possible to determine the temporal relationship between certification and admission, and/or if admitted as a transfer. Rt-PA was defined by ICD9 procedure code 99.10. All eligibility criteria were met by 323 228 discharges from 26 states. There were 63 145 (19.5%) at certified PSCs. Intravenous rt-PA was administered to 3.1% overall: 2.2% at non-PSCs and 6.7% at PSCs. Between 2004 and 2009, rt-PA administration increased from 1.4% to 3.3% at non-PSCs and from 6.0% to 7.6% at PSCs. In a multivariable model incorporating year, age, sex, race, insurance, income, comorbidities, DRG-based disease severity, and hospital characteristics, evaluation at a PSC was significantly associated with rt-PA utilization (OR, 1.87; 95% CI, 1.61 to 2.16).
  
  
  CONCLUSIONS
  Subjects evaluated at PSCs were more likely to receive rt-PA than those evaluated at non-PSCs. This association was significant after adjustment for patient and hospital-level variables. Systems of care are necessary to ensure stroke patients have rapid access to PSCs throughout the United States.
authors.affiliation: Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA. michael.mullen@uphs.upenn.edu
authors.forename: Michael T
authors.initials: MT
authors.lastname: Mullen
authors.forename: Scott E
authors.initials: SE
authors.lastname: Kasner
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Kallan
authors.forename: Dawn O
authors.initials: DO
authors.lastname: Kleindorfer
authors.forename: Karen C
authors.initials: KC
authors.lastname: Albright
authors.forename: Brendan G
authors.initials: BG
authors.lastname: Carr
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002544:Cerebral Infarction / Q000188:drug therapy*; D002568:Certification; D015331:Cohort Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006782:Hospitals, Special / Q000592:standards*; D006801:Humans; D007591:Joint Commission on Accreditation of Healthcare Organizations; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D012189:Retrospective Studies; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000706:statistics & numerical data*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014481:United States
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator
references.citation: J AHIMA. 2002 Jan;73(1):46-50
references.pmid: 12469662
references.citation: Stroke. 2011 Sep;42(9):2651-65
references.pmid: 21868727
references.citation: Stroke. 2011 Jul;42(7):1952-5
references.pmid: 21636813
references.citation: JAMA. 2000 Jun 21;283(23):3102-9
references.pmid: 10865305
references.citation: Arch Neurol. 2001 Dec;58(12):2009-13
references.pmid: 11735774
references.citation: Arch Neurol. 2004 Mar;61(3):346-50
references.pmid: 15023810
references.citation: Am J Prev Med. 2006 Dec;31(6 Suppl 2):S210-6
references.pmid: 17178305
references.citation: JAMA. 2011 Jan 26;305(4):373-80
references.pmid: 21266684
references.citation: Stroke. 2009 Nov;40(11):3574-9
references.pmid: 19797179
references.citation: Circulation. 2005 Mar 1;111(8):1078-91
references.pmid: 15738362
references.citation: Stroke. 2004 Feb;35(2):e27-9
references.pmid: 14739423
references.citation: Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:100-28
references.pmid: 22262598
references.citation: Neurology. 2001 Apr 24;56(8):1015-20
references.pmid: 11320171
references.citation: Neurology. 2005 Feb 8;64(3):422-7
references.pmid: 15699369
references.citation: N Engl J Med. 2008 Sep 25;359(13):1317-29
references.pmid: 18815396
references.citation: Neurology. 2011 Jun 7;76(23):1976-82
references.pmid: 21543736
references.citation: Stroke. 2001 May;32(5):1061-8
references.pmid: 11340210
references.citation: Stroke. 2008 Mar;39(3):924-8
references.pmid: 18239184
references.citation: Stroke. 2009 Nov;40(11):3580-4
references.pmid: 19797701
references.citation: Stroke. 2012 Mar;43(3):875-7
references.pmid: 22135073
references.citation: Med Care. 1998 Jan;36(1):8-27
references.pmid: 9431328